sucnr1 Search Results


92
Alomone Labs anti human mouse gpr91 sucnr1 fitc
Video Abstract
Anti Human Mouse Gpr91 Sucnr1 Fitc, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sucnr1/Anti-GPR91+(SUCNR1)+(extracellular)+Antibody/pmc10826047-101-27-30
Average 92 stars, based on 1 article reviews
anti human mouse gpr91 sucnr1 fitc - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

93
Addgene inc sucnr1 tango
Video Abstract
Sucnr1 Tango, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sucnr1/SUCNR1-Tango+(Plasmid+%2366507)/pm39609378-307-129-130
Average 93 stars, based on 1 article reviews
sucnr1 tango - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Novus Biologicals rabbit polyclonal anti sucnr1 gpr91
Video Abstract
Rabbit Polyclonal Anti Sucnr1 Gpr91, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sucnr1/SUCNR1%2FGPR91+Antibody+-+BSA+Free/pm40738898-489-137-143
Average 94 stars, based on 1 article reviews
rabbit polyclonal anti sucnr1 gpr91 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Novus Biologicals anti sucnr1
Video Abstract
Anti Sucnr1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sucnr1/SUCNR1%2FGPR91+Antibody+-+BSA+Free/pmc09321536-76-6-7
Average 94 stars, based on 1 article reviews
anti sucnr1 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

92
OriGene n a software
Video Abstract
N A Software, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sucnr1/GPR91+(SUCNR1)+(NM_033050)+Human+Tagged+ORF+Clone/pm38325379-193-127-116
Average 92 stars, based on 1 article reviews
n a software - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

93
Cyagen Biosciences sucnr1
Video Abstract
Sucnr1, supplied by Cyagen Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sucnr1/Sucnr1/pm41372616-440-2-5
Average 93 stars, based on 1 article reviews
sucnr1 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Taconic Biosciences sucnr1 ko mice
Figure 4. Development of a specific antagonist of <t>SUCNR1</t> and its effects in vitro (A) Schematic indicating the synthesis of compound 7a. (B) Calibration curve of cpd-7a by UV-visible (UV-vis). The absorbance of compound 7a in various concentrations was plotted against the concentration to generate the calibration curve with a goodness of fit value of 0.9993. (C) Efficacy of 7a in blocking activation of SUCNR1 by 0.5 mM succinate at the indicated concentrations in a reporter cell line. Error bars show mean ± SEM. n = 4, *p < 0.05, ***p < 0.005, ****p < 0.0001. (D and E) Representative images (D; scale bar, 150 mm) and quantitative results (E) of multinucleated (nucleus number R 10) TRAP+ primary osteoclast cultures with TRAP staining. Error bars show mean ± SEM. n = 4, *p < 0.05, **p < 0.01. (F and G) TNF-a (F) and IL-1b (G) protein levels in conditioned medium of HGF1 cells treated with LPS (5 mg/mL) for 4 and 8 h in the presence or absence of 7a (50 mM) pretreatment for 15 min as indicated. Error bars show mean ± SEM. n = 5, *p < 0.05, **p < 0.01.
Sucnr1 Ko Mice, supplied by Taconic Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sucnr1/Sucnr1/pm36130514-229-3-36
Average 93 stars, based on 1 article reviews
sucnr1 ko mice - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Novus Biologicals anti gpr91
Figure 4. Development of a specific antagonist of <t>SUCNR1</t> and its effects in vitro (A) Schematic indicating the synthesis of compound 7a. (B) Calibration curve of cpd-7a by UV-visible (UV-vis). The absorbance of compound 7a in various concentrations was plotted against the concentration to generate the calibration curve with a goodness of fit value of 0.9993. (C) Efficacy of 7a in blocking activation of SUCNR1 by 0.5 mM succinate at the indicated concentrations in a reporter cell line. Error bars show mean ± SEM. n = 4, *p < 0.05, ***p < 0.005, ****p < 0.0001. (D and E) Representative images (D; scale bar, 150 mm) and quantitative results (E) of multinucleated (nucleus number R 10) TRAP+ primary osteoclast cultures with TRAP staining. Error bars show mean ± SEM. n = 4, *p < 0.05, **p < 0.01. (F and G) TNF-a (F) and IL-1b (G) protein levels in conditioned medium of HGF1 cells treated with LPS (5 mg/mL) for 4 and 8 h in the presence or absence of 7a (50 mM) pretreatment for 15 min as indicated. Error bars show mean ± SEM. n = 5, *p < 0.05, **p < 0.01.
Anti Gpr91, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sucnr1/SUCNR1%2FGPR91+Antibody+-+BSA+Free/10__1016_slash_j__jrras__2026__102423-92-15-16
Average 93 stars, based on 1 article reviews
anti gpr91 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

91
Novus Biologicals gpr91 sucnr1 antibody
FIGURE 5. PMN depletion and <t>SUCNR1</t> inhibition eliminates succinate/LPS mediated lung injury and SUCNR1 inhibition abrogates PMN sequestration. Panel A: As compared to 50 µM succi- nate/NS, 50 µM succinate/LPS caused increased EBD leak into the BALF. In rats pre-treated with an anti-rat neutrophil antibody, the neutrophil depletion eliminates succinate [50 µM]/LPS induced ALI, as measured by levels of EBD extravasation into BALF fluid, and the EBD extravasation is not significant compared to NS/NS in the PMN depleted group (*P < 0.05 compared to 50 µM succinate/LPS). Panel B: As com- pared to the HSA/ NS/NS (Control, left panel), HSA/succi-nate [50 µM]/NS (middle panel) caused PMN infiltration/ sequestration and an increase in the thickness of the pulmonary alveolar membranes. Pretreatment with the <t>GPR91-2c</t> inhibitor, GPR91-2c/ succi- nate [50 µM]/NS decreased the num- bers of the PMNs and decreased the thickness of the pulmonary alveolar membranes (right panel). The panel is representative of experiments per- formed in duplicate. The lung sections were stained with H&E and visualized at 40X. The bar graph is the histology score, membrane thickness of the his- tology. This figure represents the quan- tification of the pulmonary alveolar thickness of 10 images from 2 separate experiments, *=P < 0.05 versus the lungs from NS/ NS controls and †=P < 0.05 versus the lungs from succinate/NS treated rats. Panel C: Pretreatment for 30 min with the GPR91-2c [30 nM] inhibitor/NS did not elicit cause ARDS, as measured by EBD leak, in rats. Rats treated with the 1.25% HSA vehicle fol- lowed by 50 µM succinate/LPS or 500 µM succinate/LPS manifested ARDS. Pretreatment with the GPR91-2c abro- gated ALI caused by 50 µM succinate/ LPS or 500 µM succi-nate/LPS (*=P < 0.05 vs GPR91-2c/NS, GPR91-2c/LPS, HSA/50 µM succinate/ NS and HSA/500 µM succinate/NS; †=P < 0.05 vs HSA/50 µM succinate/LPS and HSA/500 µM succinate/LPS, n = 5 for each bar). ARDS indicates acute respiratory distress syn- drome; LPS indicates lipopolysaccharide; HSA, human serum albumin; PMN, neutrophils; SUCNR1, succinate receptor.
Gpr91 Sucnr1 Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sucnr1/SUCNR1%2FGPR91+Antibody/10__1097_slash_sla__0000000000004644-41-16-19
Average 91 stars, based on 1 article reviews
gpr91 sucnr1 antibody - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

90
OriGene primary anti sucnr1
FIGURE 5. PMN depletion and <t>SUCNR1</t> inhibition eliminates succinate/LPS mediated lung injury and SUCNR1 inhibition abrogates PMN sequestration. Panel A: As compared to 50 µM succi- nate/NS, 50 µM succinate/LPS caused increased EBD leak into the BALF. In rats pre-treated with an anti-rat neutrophil antibody, the neutrophil depletion eliminates succinate [50 µM]/LPS induced ALI, as measured by levels of EBD extravasation into BALF fluid, and the EBD extravasation is not significant compared to NS/NS in the PMN depleted group (*P < 0.05 compared to 50 µM succinate/LPS). Panel B: As com- pared to the HSA/ NS/NS (Control, left panel), HSA/succi-nate [50 µM]/NS (middle panel) caused PMN infiltration/ sequestration and an increase in the thickness of the pulmonary alveolar membranes. Pretreatment with the <t>GPR91-2c</t> inhibitor, GPR91-2c/ succi- nate [50 µM]/NS decreased the num- bers of the PMNs and decreased the thickness of the pulmonary alveolar membranes (right panel). The panel is representative of experiments per- formed in duplicate. The lung sections were stained with H&E and visualized at 40X. The bar graph is the histology score, membrane thickness of the his- tology. This figure represents the quan- tification of the pulmonary alveolar thickness of 10 images from 2 separate experiments, *=P < 0.05 versus the lungs from NS/ NS controls and †=P < 0.05 versus the lungs from succinate/NS treated rats. Panel C: Pretreatment for 30 min with the GPR91-2c [30 nM] inhibitor/NS did not elicit cause ARDS, as measured by EBD leak, in rats. Rats treated with the 1.25% HSA vehicle fol- lowed by 50 µM succinate/LPS or 500 µM succinate/LPS manifested ARDS. Pretreatment with the GPR91-2c abro- gated ALI caused by 50 µM succinate/ LPS or 500 µM succi-nate/LPS (*=P < 0.05 vs GPR91-2c/NS, GPR91-2c/LPS, HSA/50 µM succinate/ NS and HSA/500 µM succinate/NS; †=P < 0.05 vs HSA/50 µM succinate/LPS and HSA/500 µM succinate/LPS, n = 5 for each bar). ARDS indicates acute respiratory distress syn- drome; LPS indicates lipopolysaccharide; HSA, human serum albumin; PMN, neutrophils; SUCNR1, succinate receptor.
Primary Anti Sucnr1, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sucnr1/GPR91+(SUCNR1)+Rabbit+Polyclonal+Antibody/pm29894669-89-16-18
Average 90 stars, based on 1 article reviews
primary anti sucnr1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Abbexa Ltd anti human sucnr1
Figure 2. The Na+-dependent succinate up- take by macrophages is likely mediated by an SLC13 transporter and regulated by <t>SUCNR1</t> and SLC26A6 (A) Citrate uptake was measured in either naive- or LPS/IFNg-treated RAW264.7 cells. Notably, the SLC13A5 inhibitor (inh) did not affect citrate uptake, which was increased by application of 250 mM suc- cinate (succ), potentially because of stimulation of SUCNR1, which is significantly elevated in LPS/ IFNg-treated cells. (B) Western blot analysis of SUCNR1 expression in either naive or LPS/IFNg-treated RAW264.7 macro- phages. (C) The uptake of succinate was monitored using a radiolabeled succinate flux assay in peritoneal mac- rophages that were isolated from either WT or SLC26A6/ mice. (D–F) The regulatory effect of SLC26A6 on SLC13A3- mediated succinate uptake monitored in RAW264.7 cells (D) in Xenopus oocytes (E) or in HEK293 cells (F) expressing SLC13A3 and SLC26A6, as indicated. Data are shown as means ± SEM. Statistical signifi- cance was assessed with either t test or one-way ANOVA followed by Tukey’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001.
Anti Human Sucnr1, supplied by Abbexa Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sucnr1/SUCNR1+Antibody+(HRP)/pm34380041-299-8-11
Average 90 stars, based on 1 article reviews
anti human sucnr1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Video Abstract

Journal: Cell Communication and Signaling : CCS

Article Title: Extracellular succinate derived from ectopic milieu drives adhesion and implantation growth of ectopic endometrial stromal cells via the SUCNR1 signal in endometriosis

doi: 10.1186/s12964-023-01415-7

Figure Lengend Snippet: Video Abstract

Article Snippet: The FCM antibodies used were as follows: anti-human CD86 Percp/cy5.5 (BioLegend, 305,419); anti-human/mouse MCT1 PE (R&D, FAB8275P); anti-human/Mouse GPR91/SUCNR1 FITC (Alomone, ASR-090-F); anti-mouse CD45 percp (BioLegend, 103,129); anti-human/mouse GPR91/SUCNR1 FITC (Alomone, ASR-090-F); anti-mouse CD80 PE (BioLegend, 104,707), anti-mouse CD86 ALexa fluor 700 (BioLegend, 105,024); anti-mouse CD163 BV421 (BioLegend, 155,309); anti-mouse CD206 BV605 (BioLegend, 141,721), anti-mouse CD11b PCy 7(BioLegend, 101,215); anti-mouse F4/80 APC (BioLegend, 123,116).

Techniques:

Figure 4. Development of a specific antagonist of SUCNR1 and its effects in vitro (A) Schematic indicating the synthesis of compound 7a. (B) Calibration curve of cpd-7a by UV-visible (UV-vis). The absorbance of compound 7a in various concentrations was plotted against the concentration to generate the calibration curve with a goodness of fit value of 0.9993. (C) Efficacy of 7a in blocking activation of SUCNR1 by 0.5 mM succinate at the indicated concentrations in a reporter cell line. Error bars show mean ± SEM. n = 4, *p < 0.05, ***p < 0.005, ****p < 0.0001. (D and E) Representative images (D; scale bar, 150 mm) and quantitative results (E) of multinucleated (nucleus number R 10) TRAP+ primary osteoclast cultures with TRAP staining. Error bars show mean ± SEM. n = 4, *p < 0.05, **p < 0.01. (F and G) TNF-a (F) and IL-1b (G) protein levels in conditioned medium of HGF1 cells treated with LPS (5 mg/mL) for 4 and 8 h in the presence or absence of 7a (50 mM) pretreatment for 15 min as indicated. Error bars show mean ± SEM. n = 5, *p < 0.05, **p < 0.01.

Journal: Cell reports

Article Title: Targeting the succinate receptor effectively inhibits periodontitis.

doi: 10.1016/j.celrep.2022.111389

Figure Lengend Snippet: Figure 4. Development of a specific antagonist of SUCNR1 and its effects in vitro (A) Schematic indicating the synthesis of compound 7a. (B) Calibration curve of cpd-7a by UV-visible (UV-vis). The absorbance of compound 7a in various concentrations was plotted against the concentration to generate the calibration curve with a goodness of fit value of 0.9993. (C) Efficacy of 7a in blocking activation of SUCNR1 by 0.5 mM succinate at the indicated concentrations in a reporter cell line. Error bars show mean ± SEM. n = 4, *p < 0.05, ***p < 0.005, ****p < 0.0001. (D and E) Representative images (D; scale bar, 150 mm) and quantitative results (E) of multinucleated (nucleus number R 10) TRAP+ primary osteoclast cultures with TRAP staining. Error bars show mean ± SEM. n = 4, *p < 0.05, **p < 0.01. (F and G) TNF-a (F) and IL-1b (G) protein levels in conditioned medium of HGF1 cells treated with LPS (5 mg/mL) for 4 and 8 h in the presence or absence of 7a (50 mM) pretreatment for 15 min as indicated. Error bars show mean ± SEM. n = 5, *p < 0.05, **p < 0.01.

Article Snippet: Global knockout of SUCNR1 (KO) mice were generated from EIIa-Cre (Lakso et al., 1996) (Jackson Laboratory, Bar Harbor, ME, USA) and SUCNR1 flox mice, which were created using a TurboKnockout gene targeting strategy by Cyagen and Taconic Companies.

Techniques: In Vitro, Concentration Assay, Blocking Assay, Activation Assay, Staining

Figure 7. Succinate elevation correlates with periodontitis pathogens in affected individuals (A) Heatmap for the top 40 genera based on relative abundance normalized by row Z score. (B) Correlation-based network plot of the top 40 genera and succinate level in samples. (C) Schematic summary of the role of succinate in manifestation of periodontitis; targeting SUCNR1 with 7a reduces the dysbiotic microbiome, periodontal inflammation, and bone loss; created with BioRender.

Journal: Cell reports

Article Title: Targeting the succinate receptor effectively inhibits periodontitis.

doi: 10.1016/j.celrep.2022.111389

Figure Lengend Snippet: Figure 7. Succinate elevation correlates with periodontitis pathogens in affected individuals (A) Heatmap for the top 40 genera based on relative abundance normalized by row Z score. (B) Correlation-based network plot of the top 40 genera and succinate level in samples. (C) Schematic summary of the role of succinate in manifestation of periodontitis; targeting SUCNR1 with 7a reduces the dysbiotic microbiome, periodontal inflammation, and bone loss; created with BioRender.

Article Snippet: Global knockout of SUCNR1 (KO) mice were generated from EIIa-Cre (Lakso et al., 1996) (Jackson Laboratory, Bar Harbor, ME, USA) and SUCNR1 flox mice, which were created using a TurboKnockout gene targeting strategy by Cyagen and Taconic Companies.

Techniques:

FIGURE 5. PMN depletion and SUCNR1 inhibition eliminates succinate/LPS mediated lung injury and SUCNR1 inhibition abrogates PMN sequestration. Panel A: As compared to 50 µM succi- nate/NS, 50 µM succinate/LPS caused increased EBD leak into the BALF. In rats pre-treated with an anti-rat neutrophil antibody, the neutrophil depletion eliminates succinate [50 µM]/LPS induced ALI, as measured by levels of EBD extravasation into BALF fluid, and the EBD extravasation is not significant compared to NS/NS in the PMN depleted group (*P < 0.05 compared to 50 µM succinate/LPS). Panel B: As com- pared to the HSA/ NS/NS (Control, left panel), HSA/succi-nate [50 µM]/NS (middle panel) caused PMN infiltration/ sequestration and an increase in the thickness of the pulmonary alveolar membranes. Pretreatment with the GPR91-2c inhibitor, GPR91-2c/ succi- nate [50 µM]/NS decreased the num- bers of the PMNs and decreased the thickness of the pulmonary alveolar membranes (right panel). The panel is representative of experiments per- formed in duplicate. The lung sections were stained with H&E and visualized at 40X. The bar graph is the histology score, membrane thickness of the his- tology. This figure represents the quan- tification of the pulmonary alveolar thickness of 10 images from 2 separate experiments, *=P < 0.05 versus the lungs from NS/ NS controls and †=P < 0.05 versus the lungs from succinate/NS treated rats. Panel C: Pretreatment for 30 min with the GPR91-2c [30 nM] inhibitor/NS did not elicit cause ARDS, as measured by EBD leak, in rats. Rats treated with the 1.25% HSA vehicle fol- lowed by 50 µM succinate/LPS or 500 µM succinate/LPS manifested ARDS. Pretreatment with the GPR91-2c abro- gated ALI caused by 50 µM succinate/ LPS or 500 µM succi-nate/LPS (*=P < 0.05 vs GPR91-2c/NS, GPR91-2c/LPS, HSA/50 µM succinate/ NS and HSA/500 µM succinate/NS; †=P < 0.05 vs HSA/50 µM succinate/LPS and HSA/500 µM succinate/LPS, n = 5 for each bar). ARDS indicates acute respiratory distress syn- drome; LPS indicates lipopolysaccharide; HSA, human serum albumin; PMN, neutrophils; SUCNR1, succinate receptor.

Journal: Annals of Surgery

Article Title: Succinate Activation of SUCNR1 Predisposes Severely Injured Patients to Neutrophil-mediated ARDS

doi: 10.1097/sla.0000000000004644

Figure Lengend Snippet: FIGURE 5. PMN depletion and SUCNR1 inhibition eliminates succinate/LPS mediated lung injury and SUCNR1 inhibition abrogates PMN sequestration. Panel A: As compared to 50 µM succi- nate/NS, 50 µM succinate/LPS caused increased EBD leak into the BALF. In rats pre-treated with an anti-rat neutrophil antibody, the neutrophil depletion eliminates succinate [50 µM]/LPS induced ALI, as measured by levels of EBD extravasation into BALF fluid, and the EBD extravasation is not significant compared to NS/NS in the PMN depleted group (*P < 0.05 compared to 50 µM succinate/LPS). Panel B: As com- pared to the HSA/ NS/NS (Control, left panel), HSA/succi-nate [50 µM]/NS (middle panel) caused PMN infiltration/ sequestration and an increase in the thickness of the pulmonary alveolar membranes. Pretreatment with the GPR91-2c inhibitor, GPR91-2c/ succi- nate [50 µM]/NS decreased the num- bers of the PMNs and decreased the thickness of the pulmonary alveolar membranes (right panel). The panel is representative of experiments per- formed in duplicate. The lung sections were stained with H&E and visualized at 40X. The bar graph is the histology score, membrane thickness of the his- tology. This figure represents the quan- tification of the pulmonary alveolar thickness of 10 images from 2 separate experiments, *=P < 0.05 versus the lungs from NS/ NS controls and †=P < 0.05 versus the lungs from succinate/NS treated rats. Panel C: Pretreatment for 30 min with the GPR91-2c [30 nM] inhibitor/NS did not elicit cause ARDS, as measured by EBD leak, in rats. Rats treated with the 1.25% HSA vehicle fol- lowed by 50 µM succinate/LPS or 500 µM succinate/LPS manifested ARDS. Pretreatment with the GPR91-2c abro- gated ALI caused by 50 µM succinate/ LPS or 500 µM succi-nate/LPS (*=P < 0.05 vs GPR91-2c/NS, GPR91-2c/LPS, HSA/50 µM succinate/ NS and HSA/500 µM succinate/NS; †=P < 0.05 vs HSA/50 µM succinate/LPS and HSA/500 µM succinate/LPS, n = 5 for each bar). ARDS indicates acute respiratory distress syn- drome; LPS indicates lipopolysaccharide; HSA, human serum albumin; PMN, neutrophils; SUCNR1, succinate receptor.

Article Snippet: PMNs were incubated with NS or succinate (500–1000 μM), fixed, smeared onto slides, incubated with a GPR91/ SUCNR1 antibody (Novus Biological, Littleton, CO), and then with a species-specific fluorescent antibody followed by microscopic imaging at 100X magnification.20,34 SUCNR1 Inhibitor Synthesis and Inhibition of

Techniques: Inhibition, Control, Staining, Membrane

Figure 2. The Na+-dependent succinate up- take by macrophages is likely mediated by an SLC13 transporter and regulated by SUCNR1 and SLC26A6 (A) Citrate uptake was measured in either naive- or LPS/IFNg-treated RAW264.7 cells. Notably, the SLC13A5 inhibitor (inh) did not affect citrate uptake, which was increased by application of 250 mM suc- cinate (succ), potentially because of stimulation of SUCNR1, which is significantly elevated in LPS/ IFNg-treated cells. (B) Western blot analysis of SUCNR1 expression in either naive or LPS/IFNg-treated RAW264.7 macro- phages. (C) The uptake of succinate was monitored using a radiolabeled succinate flux assay in peritoneal mac- rophages that were isolated from either WT or SLC26A6/ mice. (D–F) The regulatory effect of SLC26A6 on SLC13A3- mediated succinate uptake monitored in RAW264.7 cells (D) in Xenopus oocytes (E) or in HEK293 cells (F) expressing SLC13A3 and SLC26A6, as indicated. Data are shown as means ± SEM. Statistical signifi- cance was assessed with either t test or one-way ANOVA followed by Tukey’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001.

Journal: Cell reports

Article Title: A transepithelial pathway delivers succinate to macrophages, thus perpetuating their pro-inflammatory metabolic state.

doi: 10.1016/j.celrep.2021.109521

Figure Lengend Snippet: Figure 2. The Na+-dependent succinate up- take by macrophages is likely mediated by an SLC13 transporter and regulated by SUCNR1 and SLC26A6 (A) Citrate uptake was measured in either naive- or LPS/IFNg-treated RAW264.7 cells. Notably, the SLC13A5 inhibitor (inh) did not affect citrate uptake, which was increased by application of 250 mM suc- cinate (succ), potentially because of stimulation of SUCNR1, which is significantly elevated in LPS/ IFNg-treated cells. (B) Western blot analysis of SUCNR1 expression in either naive or LPS/IFNg-treated RAW264.7 macro- phages. (C) The uptake of succinate was monitored using a radiolabeled succinate flux assay in peritoneal mac- rophages that were isolated from either WT or SLC26A6/ mice. (D–F) The regulatory effect of SLC26A6 on SLC13A3- mediated succinate uptake monitored in RAW264.7 cells (D) in Xenopus oocytes (E) or in HEK293 cells (F) expressing SLC13A3 and SLC26A6, as indicated. Data are shown as means ± SEM. Statistical signifi- cance was assessed with either t test or one-way ANOVA followed by Tukey’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: Immunohistochemistry (IHC) was performed using the following antibodies: anti-human SUCNR1 (1:200; Abbexa, Cambridge, UK), anti-human SLC26A6 (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA).

Techniques: Western Blot, Expressing, Isolation

Figure 4. The expression of determinants that either inhibit succinate uptake or mediate succinate clearance in intestinal and colon tissues of IBD patients (A and B) Representative images of immunohisto- chemistry analysis (A) and summary (B) of SUCNR1 protein expression in the intestine of either healthy conrol (HC), Crohn’s disease (CD), or ulcerative colitis (UC) patients. SUCNR1 expres- sion was detected in epithelial cells and in the lamina propria (arrows). (C) The gene expression of SUCNR1 in colon tis- sues of HCs, CD patients, or UC patients. (D and E) Representative images of immunofluo- rescence analysis (D) and summary (E) of SLC26A6 protein expression (green) in the intestine of HCs, CD patients, or UC patients. SLC26A6 expression was mainly detected in epithelial cells (arrows). Red arrows and blue arrows indicate the apical side of epithelial cells and macrophages, respec- tively. Nuclei were counterstained with DAPI (blue). (F–H) The gene expression of SLC26A6 (F), SLC26A3 (G), and SLC13A3 (H) was monitored in colon tissues of HCs, CD patients, or UC patients, as indicated. The transcript levels were quantified by real-time qRT-PCR. Data are shown as means ± SEM. Statistical sig- nificance was assessed using one-way ANOVA Kruskal-Wallis test followed by Dunn’s post-test. *p < 0.05, **p < 0.01.

Journal: Cell reports

Article Title: A transepithelial pathway delivers succinate to macrophages, thus perpetuating their pro-inflammatory metabolic state.

doi: 10.1016/j.celrep.2021.109521

Figure Lengend Snippet: Figure 4. The expression of determinants that either inhibit succinate uptake or mediate succinate clearance in intestinal and colon tissues of IBD patients (A and B) Representative images of immunohisto- chemistry analysis (A) and summary (B) of SUCNR1 protein expression in the intestine of either healthy conrol (HC), Crohn’s disease (CD), or ulcerative colitis (UC) patients. SUCNR1 expres- sion was detected in epithelial cells and in the lamina propria (arrows). (C) The gene expression of SUCNR1 in colon tis- sues of HCs, CD patients, or UC patients. (D and E) Representative images of immunofluo- rescence analysis (D) and summary (E) of SLC26A6 protein expression (green) in the intestine of HCs, CD patients, or UC patients. SLC26A6 expression was mainly detected in epithelial cells (arrows). Red arrows and blue arrows indicate the apical side of epithelial cells and macrophages, respec- tively. Nuclei were counterstained with DAPI (blue). (F–H) The gene expression of SLC26A6 (F), SLC26A3 (G), and SLC13A3 (H) was monitored in colon tissues of HCs, CD patients, or UC patients, as indicated. The transcript levels were quantified by real-time qRT-PCR. Data are shown as means ± SEM. Statistical sig- nificance was assessed using one-way ANOVA Kruskal-Wallis test followed by Dunn’s post-test. *p < 0.05, **p < 0.01.

Article Snippet: Immunohistochemistry (IHC) was performed using the following antibodies: anti-human SUCNR1 (1:200; Abbexa, Cambridge, UK), anti-human SLC26A6 (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA).

Techniques: Expressing, Immunohistochemistry, Gene Expression, Quantitative RT-PCR